Advertisement

Just a few months after it won a key patent, Ariad Pharmaceuticals Inc. (Nasdaq: ARIA) has submitted a new drug application to the U.S. Food and Drug Administration for its investigational drug ponatinib to treat a rare form of leukemia, the company said Tuesday.

Advertisement
Advertisement